ESMO 2019: New data to extend Lynparza leadership

16 September 2019

At the upcoming annual meeting of the European Society for Medical Oncology (ESMO), UK-based drugmaker AstraZeneca (LSE: AZN) will present data in 63 abstracts, including in Presidential Symposia across three cancer types.

This year, the ESMO Congress is taking place in Barcelona, Spain, from September 27 to October 1. AstraZeneca has a total of seven oral presentations, with highlights in precision medicine and immunotherapy.

Investors will look in particular for new data from the Phase III FLAURA trial in lung cancer, which will provide details of overall survival (OS) benefit of Tagrisso (osimertinib) compared with previous standard-of-care treatments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK